2. As of noon trading, Celgene Corporation ( CELG) is down $0.93 (-0.6%) to $148.55 on average volume. Thus far, 1.4 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $147.95-$151.20 after having opened the day at $150.80 as compared to the previous trading day's close of $149.48.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $61.5 billion and is part of the health care sector. Shares are up 90.7% year to date as of the close of trading on Friday. Currently there are 20 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, notable return on equity and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Celgene Corporation Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Novartis CEO Joe Jimenez to Step Down in 2018

FDA Greenlights Novartis' Gene Therapy for Leukemia

Novartis' CAR-T Gene Therapy Receives FDA Approval

Novartis AG, Sirius XM Radio, Coupa Software: 'Mad Money' Lightning Round

August's Inexplicable Selloffs Are Here: Cramer's 'Mad Money' Recap (8/17/17)